- Home
- CNTB vs QNCX Comparison
CNTB vs QNCX Comparison
Compare CNTB & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- QNCX
- Stock Information
- Founded
- CNTB 2012
- QNCX 2012
- Country
- CNTB United States
- QNCX United States
- Employees
- CNTB N/A
- QNCX N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNTB Health Care
- QNCX Health Care
- Exchange
- CNTB Nasdaq
- QNCX Nasdaq
- Market Cap
- CNTB 44.2M
- QNCX 47.7M
- IPO Year
- CNTB 2021
- QNCX 2019
- Fundamental
- Price
- CNTB $1.00
- QNCX $1.50
- Analyst Decision
- CNTB Strong Buy
- QNCX Strong Buy
- Analyst Count
- CNTB 2
- QNCX 5
- Target Price
- CNTB $7.50
- QNCX $8.00
- AVG Volume (30 Days)
- CNTB 93.6K
- QNCX 305.4K
- Earning Date
- CNTB 05-15-2025
- QNCX 08-12-2025
- Dividend Yield
- CNTB N/A
- QNCX N/A
- EPS Growth
- CNTB N/A
- QNCX N/A
- EPS
- CNTB N/A
- QNCX N/A
- Revenue
- CNTB $26,033,000.00
- QNCX N/A
- Revenue This Year
- CNTB N/A
- QNCX N/A
- Revenue Next Year
- CNTB N/A
- QNCX N/A
- P/E Ratio
- CNTB N/A
- QNCX N/A
- Revenue Growth
- CNTB N/A
- QNCX N/A
- 52 Week Low
- CNTB $0.51
- QNCX $0.51
- 52 Week High
- CNTB $1.73
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- CNTB 59.56
- QNCX 65.33
- Support Level
- CNTB $0.91
- QNCX $1.29
- Resistance Level
- CNTB $1.12
- QNCX $1.62
- Average True Range (ATR)
- CNTB 0.08
- QNCX 0.11
- MACD
- CNTB 0.01
- QNCX 0.03
- Stochastic Oscillator
- CNTB 59.26
- QNCX 74.47
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.